ClinicalTrials.gov
public full text
Public Domain
Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With Cancer
This is a randomized, single dose, open-label, multicenter crossover study to determine the oral bioavailability of a new ABT-263 formulation relative to that of the current ABT-263 formulation being administered in ongoing Phase 1/2a studies. Approximately 48 evaluable subjects with lymphoid malignancies, including chronic lymphocytic leukemia, and solid tumors will be enrolled in this study.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Assess the Oral Bioavailability of New ABT-263 Formulations#880350
- To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients#888218
- Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors#839548
- A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies#910368
- An Open-Label Phase-1 Study of OPB-31121 in Patients With Advanced Solid Tumors#850016
Record · ID 992517
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive